Over 50% of all Israeli citizens have now received at least one Covid-19 vaccination, with 3 million (nearly one-third) having had both. The Pfizer vaccine is shown to be 95.8% effective in preventing new Covid-19 infections and nearly 99% effective … Continue reading →

Tel Aviv University researchers have developed a biological antibiotic derived from human monoclonal antibodies, as an alternative to traditional chemical antibiotics. The antibodies were taken from a recovered tuberculosis patient and were shown to kill TB bacteria – still a … Continue reading →

Surgeons at the Baruch Padeh Medical Center near Tiberias saved the eye of a fisherman who accidentally speared himself with his own fishhook. The delicate operation included cutting the hook, releasing the eye tissue and repairing the eyeball. The doctors … Continue reading →

Israeli-founded Dendro Technolgies and its Calmigo handheld device (reported here previously) are helping to make life less stressful for those struggling to cope in a coronavirus world.  The US Veterans Administration is giving Calmigo free to veterans and the IRS … Continue reading →

Israel’s CardiacSense has received the European CE Mark for its medical-grade wristwatch that continually measures heart rate and arrhythmias. It is the first time an official regulator has approved such a device. CardiacSense has distribution agreements worth some $100 million. … Continue reading →

Ben Gurion University researchers have invented a miniaturized micro-electrode sensor that accurately checks clozapine levels in a tiny sample of blood obtained by a simple finger prick. Clozapine treats schizophrenia but the sensor is the basis for monitoring many other … Continue reading →

On 2nd Mar, the JNF is hosting a webinar featuring Israeli and US innovations in the Life Sciences. It includes the Chief Scientific & Medical Officer Prof. Dror Mevorach of Israel’s Enlivex Therapeutics – developer of COVID-19 “cure” Allocetra.  Registration … Continue reading →

Israel’s Gamida Cell (reported here previously) published the results of its Phase 3 trial of omidubicel (previously NiCord) in blood-based cancer patients. The treatment resulted in faster blood count recovery, fewer bacterial and viral infections, and fewer days in the … Continue reading →